Lexaria Bioscience Corp (LEXX) - Total Assets
Based on the latest financial reports, Lexaria Bioscience Corp (LEXX) holds total assets worth $6.49 Million USD as of February 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check Lexaria Bioscience Corp total reinvestment intensity to assess the company's total reinvestment commitment from operating cash flow.
Lexaria Bioscience Corp - Total Assets Trend (2005–2025)
This chart illustrates how Lexaria Bioscience Corp's total assets have evolved over time, based on quarterly financial data. Check LEXX cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Lexaria Bioscience Corp - Asset Composition Analysis
Current Asset Composition (August 2025)
Lexaria Bioscience Corp's total assets of $6.49 Million consist of 83.1% current assets and 16.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 43.2% |
| Accounts Receivable | $368.36K | 8.8% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $307.82K | 7.4% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2005–2025)
This chart illustrates how Lexaria Bioscience Corp's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Lexaria Bioscience Corp market cap and net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Lexaria Bioscience Corp's current assets represent 83.1% of total assets in 2025, an increase from 80.1% in 2005.
- Cash Position: Cash and equivalents constituted 43.2% of total assets in 2025, down from 78.5% in 2005.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 7.0% of total assets, an increase from 0.0% in 2005.
- Asset Diversification: The largest asset category is accounts receivable at 8.8% of total assets.
Lexaria Bioscience Corp Competitors by Total Assets
Key competitors of Lexaria Bioscience Corp based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC
|
USA | $4.40K |
|
Krystal Biotech Inc
NASDAQ:KRYS
|
USA | $1.40 Billion |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
Lexaria Bioscience Corp - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 26.88 | 4.24 | 43.78 |
| Quick Ratio | 26.88 | 4.24 | 43.55 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $5.56 Million | $5.90 Million | $9.46 Million |
Lexaria Bioscience Corp - Advanced Valuation Insights
This section examines the relationship between Lexaria Bioscience Corp's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.32 |
| Latest Market Cap to Assets Ratio | 3.62 |
| Asset Growth Rate (YoY) | -52.9% |
| Total Assets | $4.18 Million |
| Market Capitalization | $15.12 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Lexaria Bioscience Corp's assets at a significant premium (3.62x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Lexaria Bioscience Corp's assets decreased by 52.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Lexaria Bioscience Corp (2005–2025)
The table below shows the annual total assets of Lexaria Bioscience Corp from 2005 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-08-31 | $4.18 Million | -52.92% |
| 2024-08-31 | $8.87 Million | +187.54% |
| 2023-08-31 | $3.08 Million | -60.63% |
| 2022-08-31 | $7.83 Million | -40.95% |
| 2021-08-31 | $13.27 Million | +369.08% |
| 2020-08-31 | $2.83 Million | +5.72% |
| 2019-08-31 | $2.68 Million | +10.01% |
| 2018-08-31 | $2.43 Million | -14.98% |
| 2017-08-31 | $2.86 Million | +404.76% |
| 2016-08-31 | $566.64K | -20.38% |
| 2015-08-31 | $711.72K | -80.08% |
| 2014-08-31 | $3.57 Million | 0.00% |
| 2013-08-31 | $3.57 Million | -2.98% |
| 2012-08-31 | $3.68 Million | -15.13% |
| 2011-08-31 | $4.34 Million | +12.28% |
| 2010-08-31 | $3.86 Million | +13.06% |
| 2009-08-31 | $3.42 Million | +5.18% |
| 2008-08-31 | $3.25 Million | -14.38% |
| 2007-08-31 | $3.80 Million | +39.59% |
| 2006-08-31 | $2.72 Million | +147.09% |
| 2005-08-31 | $1.10 Million | -- |
About Lexaria Bioscience Corp
Lexaria Bioscience Corp. operates as a biotechnology company. The company offers its patented drug delivery-enabling platform technology, DehydraTECH, which combines active pharmaceutical ingredients (APIs) with specific long-chain fatty acid-rich triglyceride oils and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall … Read more